Eli Lilly launched TuneLab, an AI platform granting early-stage biotechs access to its sophisticated drug discovery models in exchange for data contributions. This initiative, part of Lilly’s Catalyze360 program, aims to democratize AI tools by fostering data sharing while protecting proprietary information through federated learning technology. Separately, Promega licensed engineered reverse transcriptase enzymes from Watchmaker Genomics, enhancing sensitive RNA-based assay accuracy for diagnostics and pharmaceutical research.